Akari Therapeutics, Plc Cash and Cash Equivalents
Akari Therapeutics, Plc (AKTX) had Cash and Cash Equivalents of $7.69 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash and Cash Equivalent
us-gaap:CashAndCashEquivalentsAtCarryingValue · last filed 2026-08-13
- 2026-06-30: Cash and Cash Equivalents, at Carrying Value $7.69M.
- 2026-03-31: Cash and Cash Equivalents, at Carrying Value $2.77M.
- 2025-12-31: Cash and Cash Equivalents, at Carrying Value $5.20M; Cash and Cash Equivalents, at Carrying Value as first filed $0.00.
- 2025-06-30: Cash and Cash Equivalents, at Carrying Value $2.71M.
| Period end | Cash and Cash Equivalents, at Carrying Value | Cash and Cash Equivalents, at Carrying Value as first filed |
|---|---|---|
| 2026-06-30 | $7.69M 10-Q · filed 2026-08-13 | |
| 2026-03-31 | $2.77M 10-Q · filed 2026-05-19 | |
| 2025-12-31 | $5.20M 10-Q · filed 2026-08-13 | $0.00 10-K · filed 2026-03-30 |
| 2025-06-30 | $2.71M 10-Q · filed 2025-08-13 | |
| 2025-03-31 | $2.58M 10-Q · filed 2025-05-14 | |
| 2024-12-31 | $0.00 10-K · filed 2026-03-30 | $2.60M 10-K · filed 2025-04-15 |
| 2024-09-30 | $2.25M 10-Q · filed 2024-11-19 | |
| 2024-06-30 | $235.77K 8-K · filed 2024-09-06 | $4.18M 10-Q · filed 2024-08-19 |
| 2024-03-31 | $1.31M 10-Q · filed 2024-05-15 | |
| 2023-12-31 | $3.85M 10-K · filed 2025-04-15 | |
| 2023-06-30 | $214.37K 8-K · filed 2024-09-06 | $7.18M 6-K · filed 2023-09-29 |
| 2022-12-31 | $654.89K 8-K · filed 2024-09-06 | $13.25M 20-F · filed 2023-05-01 |
| 2022-06-30 | $8.15M 6-K · filed 2022-09-27 | |
| 2021-12-31 | $9.36M 20-F · filed 2023-05-01 | |
| 2021-06-30 | $3.79M 6-K · filed 2021-09-22 | |
| 2020-12-31 | $14.06M 20-F · filed 2022-05-16 | |
| 2020-09-30 | $12.32M 20-F · filed 2021-04-21 | |
| 2020-06-30 | $12.75M 20-F · filed 2021-04-21 | |
| 2020-03-31 | $7.82M 20-F · filed 2021-04-21 | |
| 2019-12-31 | $5.73M 20-F · filed 2021-04-21 | |
| 2019-09-30 | $6.27M 20-F · filed 2021-04-21 | |
| 2019-06-30 | $2.74M 20-F · filed 2021-04-21 | |
| 2019-03-31 | $6.15M 20-F · filed 2021-04-21 | |
| 2018-12-31 | $5.45M 20-F · filed 2020-03-31 | |
| 2018-06-30 | $15.07M 6-K · filed 2018-09-27 | |
| 2017-12-31 | $28.11M 20-F · filed 2020-03-31 | |
| 2017-06-30 | $30.12M 6-K · filed 2018-09-27 | |
| 2016-12-31 | $34.10M 6-K · filed 2018-09-27 | |
| 2016-06-30 | $9.66M 6-K · filed 2017-08-10 | |
| 2016-03-31 | $61.43M 10-Q · filed 2016-05-12 | |
| 2015-12-31 | $68.92M 20-F · filed 2018-07-18 | |
| 2015-09-30 | $78.77M 10-Q · filed 2015-11-23 | |
| 2015-06-30 | $201.44K 6-K · filed 2017-04-14 | $2.72M 10-Q · filed 2015-08-12 |
| 2015-03-31 | $1.33M 10-Q · filed 2016-05-12 | $4.02M 10-Q · filed 2015-05-12 |
| 2014-12-31 | $3.33M 20-F · filed 2018-07-18 | $6.22M 10-K · filed 2015-02-11 |
| 2014-09-30 | $52.61K 10-Q · filed 2015-11-23 | |
| 2014-06-30 | $11.36M 10-Q · filed 2015-08-12 | |
| 2014-03-31 | $13.83M 10-Q · filed 2015-05-12 | |
| 2013-12-31 | $553.65K 20-F · filed 2017-03-31 | $7.66M 20-F · filed 2014-03-24 |
| 2012-12-31 | $1.10M 10-K · filed 2015-02-11 | |
| 2011-12-31 | $6.00K 10-K · filed 2015-02-11 | |
| 2010-12-31 | $9.00K 20-F · filed 2014-03-24 | |
| 2009-12-31 | $3.00K 20-F/A · filed 2013-04-19 | |
| 2004-10-06 | $0.00 20-F · filed 2014-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ELI LILLY & Co (LLY) | United States | $1,113.804B | 42.28 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |